The Cystic Fibrosis Foundation (CFF) has awarded $1.6 million to support research focused on identifying biomarkers of chronic lung allograft dysfunction (CLAD) — a complication of lung transplants — in people with cystic fibrosis (CF). A total of eight grants have been awarded, which will each focus on…
Home monitoring with a mobile phone-linked spirometry device may provide an effective way of detecting pulmonary exacerbations — episodes of a sudden worsening of respiratory symptoms — in people with cystic fibrosis (CF), a pilot study suggests. The findings showed more pulmonary exacerbations were identified through home monitoring…
The first patient has been dosed in a Phase 1/2 clinical trial evaluating 4D-710, an investigational genetic medicine for adults with cystic fibrosis (CF), its maker, 4D Molecular Therapeutics (4DMT) has announced. “The dosing of the first patient in the 4D-710 Phase 1/2 clinical trial in cystic fibrosis…
A new online exercise and yoga program for children and adolescents living with cystic fibrosis (CF) is in development by Beam and CF Yogi, and will launch — with no costs to youth — in August on Beam’s virtual well-being platform. The program, created with the Johns…
A noninvasive measurement of lung function called lung clearance index (LCI) was associated with the degree of lung damage over time in children with cystic fibrosis (CF), according to a recent study. LCI could be used to monitor lung disease progression in children with CF and may help clinicians…
KIT2014, an experimental treatment that Kither Biotech is developing to treat cystic fibrosis (CF) and other lung diseases, was able to reduce inflammation, relax the airways, and improve the functionality of CFTR modulators in preclinical models, a study shows. Kither is planning to launch a Phase 1/2a clinical…
In children with cystic fibrosis (CF) and a first or new-onset Pseudomonas aeruginosa infection, antibiotics given intravenously are not more effective at eliminating the bacteria than inhaled antibiotics given alone or as combination therapy, a Turkish study suggests. Intravenous (IV) treatment was also associated with more pulmonary exacerbations and poorer lung function after…
The Cystic Fibrosis Foundation (CFF) has awarded up to $15.9 million to Eloxx Pharmaceuticals to support the company’s clinical program for ELX-02, an investigational therapy for cystic fibrosis (CF) patients with nonsense mutations. A total of $7 million will be provided upfront, with additional funding granted based on…
Beginning April 1 the Australian government will subsidize the cost of Trikafta (elexacaftor/tezacaftor/ivacaftor) for patients with cystic fibrosis (CF) under the Australian Pharmaceutical Benefits Scheme (PBS), dramatically reducing out-of-pocket expenses for eligible Australians. The subsidy was made possible by a reimbursement agreement reached between Trikafta’s developer, Vertex…
Health Canada has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in patients 4 months to 18 years old who carry the R117H mutation in the CFTR gene, and who weigh at least five kilograms (about 11 pounds). “It’s been our goal to ensure that…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.